The final one to report should be Northwest Biotech (NASDAQ: NWBO) with their phase 3 Glioblastoma trial. They are in the same situation as CVM, the data is locked and they are waiting for the final trial results report which could come at any moment, but it is likely to come before the shareholder meeting in April. Positive results from any of these famous Feuerstein pans could mean the end of his career and him drifting off into the journalistic sunset.
Market Data 
Markets 
AI
